Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Psoriatic arthritis.

Philippe Goupille1

  • 1EA 3853 Immuno-Pharmaco-Génétics of Therapeutic Antibodies (IPGA), and Rheumatology Department, Trousseau Teaching Hospital, François Rabelais University, 37044 Tours cedex 9, France. goupille@med.univ-tours.fr

Joint Bone Spine
|November 29, 2005
PubMed
Summary

Psoriatic arthritis management is evolving with new research. Biotherapies, particularly TNF-alpha antagonists, represent a breakthrough, necessitating updated evaluation tools and treatment strategies for this complex condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypertrophic Osteoarthropathy Revealing an Esophageal Tumor.

Joint bone spine·2026
Same authorSame journal

Psoriatic arthritis phase 3 trials: larger effects, but for whom?

Joint bone spine·2026
Same author

Efficacy of Ixekizumab in Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level: A Pooled Analysis of Phase III Trials.

Rheumatology and therapy·2026
Same author

The changing face of axial spondyloarthritis over the last 25 years.

Joint bone spine·2025
Same author

Navigating clinical research challenges in spondyloarthritis: Insights from the French Spondyloarthritis Taskforce (FAST).

Joint bone spine·2025
Same author

When generative artificial intelligence answers to Google Trends about spondyloarthritis: what does a French expert panel think about it?

RMD open·2025

Area of Science:

  • Rheumatology and immunology
  • Inflammatory disease research

Background:

  • Psoriatic arthritis presents unique management challenges.
  • Recent advancements offer new insights into its epidemiology, diagnosis, and treatment.
  • Introduction of biotherapies necessitates re-evaluation of assessment methods.

Purpose of the Study:

  • To review recent advancements in psoriatic arthritis research.
  • To highlight the impact of biotherapies on disease management.
  • To discuss the evolving landscape of psoriatic arthritis evaluation and treatment.

Main Methods:

  • Literature review of recent studies on psoriatic arthritis.
  • Analysis of new knowledge in epidemiology, diagnostics, and prognostics.
  • Evaluation of the role and impact of biotherapies, including TNF-alpha antagonists.

Main Results:

  • Significant research progress has been made across multiple domains of psoriatic arthritis.
  • Biotherapies, especially TNF-alpha antagonists, have emerged as a major therapeutic advance.
  • These advancements require updated tools for evaluating disease status and treatment efficacy.

Conclusions:

  • Psoriatic arthritis management is entering a new phase driven by research and novel therapies.
  • Effective use of biotherapies requires refined outcome prediction and evaluation parameters.
  • The field mirrors progress seen in rheumatoid arthritis and ankylosing spondylitis management.

Related Experiment Videos